---
document_datetime: 2023-09-21 19:55:57
document_pages: 13
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/clopidogrel-bgr-previously-zylagren-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: clopidogrel-bgr-previously-zylagren-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.9554673
conversion_datetime: 2025-12-25 05:07:40.813483
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Clopidogrel BGR

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0040              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 24/02/2020                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0039     | - Change in immediate packaging of the product - Qualitative and quantitative - Solid pharmaceutical forms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 22/11/2019   | n/a        |                                  | B.II.e.1.a.1 finished composition   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------------------------|
| IAIN/0038/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 23/10/2019   | n/a        |                                  | site                                |
| IB/0037/G   | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following | 25/09/2019   | 24/10/2019 | SmPC, Annex II, Labelling and PL |                                     |

<div style=\"page-break-after: always\"></div>

|           | - Implementation of change(s) for which NO additional data is required to be submitted by MAH                                                                                                                                                                                                                                                                                                      |            |            |                        | product new the   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------|
| IB/0036   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                       | 05/06/2019 | 24/10/2019 | SmPC, Labelling and PL |                   |
| IB/0035   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                          | 26/04/2019 | 24/10/2019 | SmPC                   |                   |
| IB/0034   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                       | 26/04/2018 | 02/04/2019 | SmPC and PL            |                   |
| IA/0033/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch | 20/03/2018 | n/a        |                        |                   |

<div style=\"page-break-after: always\"></div>

|           | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                |            |            |                        |         |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------|
| IA/0032   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                      | 18/01/2018 | n/a        |                        | from an |
| IB/0031/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by MAH | 22/06/2017 | 19/07/2017 | SmPC, Labelling and PL | the     |
| IA/0030   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                            | 09/06/2017 | n/a        |                        | in the  |

<div style=\"page-break-after: always\"></div>

| IB/0029/G   | This was an application for a group of variations. B.II.e.1.b.1 - Change in immediate packaging of the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 08/06/2016   | 22/05/2017   | SmPC, Labelling and PL   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|
| IB/0028/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 08/12/2015   | 02/06/2016   | SmPC, Annex II and PL    |

<div style=\"page-break-after: always\"></div>

| IAIN/0027   | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                           | 30/09/2015   | 02/06/2016   | Annex II and PL   |                  |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|------------------|
| IAIN/0026   | B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer                                                              | 30/09/2015   | n/a          |                   |                  |
| IB/0025     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 12/06/2015   | 02/06/2016   | SmPC and PL       | the MAH          |
| IAIN/0024/G | application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging                | 02/12/2014   | n/a          |                   | This was an site |
| IAIN/0023   | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                                       | 27/10/2014   | n/a          |                   |                  |

<div style=\"page-break-after: always\"></div>

| IB/0022           | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                       | 07/10/2014   | n/a        |                        |                                                                                                   |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|---------------------------------------------------------------------------------------------------|
| IAIN/0021         | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                           | 15/09/2014   | n/a        |                        |                                                                                                   |
| T/0020            | Transfer of marketing authorisation from Krka, d.d., Novo mesto to Laboratoires BIOGARAN, France. Transfer of Marketing Authorisation                                                                                                     | 15/07/2014   | 27/08/2014 | SmPC, Labelling and PL | Transfer of marketing authorisation from Krka, d.d., Novo mesto to Laboratoires BIOGARAN, France. |
| IB/0018           | B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products | 25/07/2014   | n/a        |                        |                                                                                                   |
| IAIN/0019         | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs                                                                                                                                           | 14/07/2014   | 27/08/2014 | SmPC, Labelling and PL |                                                                                                   |
| PSUSA/820/2 01311 | Periodic Safety Update EU Single assessment - acetylsalicylic acid / clopidogrel, clopidogrel                                                                                                                                             | 10/07/2014   | n/a        |                        | PRAC Recommendation - maintenance                                                                 |
| IAIN/0017/G       | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters                                                                                                                                     | 23/05/2014   | n/a        |                        |                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0013    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                           | 20/03/2014 | 08/05/2014 | SmPC and PL | The safety and efficacy of clopidogrel have been demonstrated by several large clinical studies. No literature review on the efficacy/effectiveness has been submitted by the MAH within this application. Since the clinical efficacy of clopidogrel in the approved indications is well established and evidence of clinical efficacy has been discussed at time of approval the CHMP finds acceptable the MAH approach of not performing a literature review on the efficacy/effectiveness of clopidogrel. The beneficial effect of Zylagren remains in line with that of the originator product (Plavix), and is considered positive. The CHMP therefore recommended that the Marketing Authorisation for Zylagren can be renewed with unlimited validity. |
| IB/0016/G | This was an application for a group of variations. To update sections 4.4 and 4.5 of the SmPC to add information on an interaction with the selective serotonin reuptake inhibitors (SSRIs) in section 4.5 and consequential information concerning this interaction in section 4.4. The Package leaflet has been updated accordingly.            | 23/04/2014 | 27/08/2014 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|           | To update 4.8 of the SmPC to add \"Rash exfoliative\" as a new undesirable effect. Furthermore minor editorial correction to DE, HR, NO and PL text were introduced. These changes have been previously approved for the reference medicinal product Plavix in WS/476 and WS/477 respectively. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0012/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 24/02/2014 | n/a |

<div style=\"page-break-after: always\"></div>

| IB/0014   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                 | 19/02/2014   | 08/05/2014   | SmPC                      |                 |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------------------|-----------------|
| IAIN/0011 | B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 13/12/2013   | 08/05/2014   | Annex II and PL           | Including batch |
| IA/0010   | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                               | 09/12/2013   | n/a          |                           |                 |
| IB/0009/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 21/10/2013   | 08/05/2014   | SmPC                      |                 |
| IB/0008/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 05/08/2013   | 08/05/2014   | SmPC, Annex II, Labelling |                 |

<div style=\"page-break-after: always\"></div>

|           | the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH   |            |     | and PL   | C.I.2.a - Change in   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|-----------------------|
| IA/0007/G | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch                                                                                                       | 17/12/2012 | n/a |          | size                  |
| IB/0006/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size Administrative change - Deletion of                                                                                                     | 21/11/2012 | n/a |          | A.7 -                 |

<div style=\"page-break-after: always\"></div>

|           | manufacturing sites B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                       |            |     |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0005/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO | 29/08/2011 | n/a | SmPC                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IB/0004   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                      | 15/04/2011 | n/a | SmPC, Annex II and PL | To update SPC sections 4.2 \"Posology and method of administration\", 4.4 \"Special warnings and precautions for use\", 4.5 \"Interaction with other medicinal products and other forms of interaction\" and 5.2 \"Pharmacokinetic properties\" of clopidogrel/acetyisalicylic acid (ASA) SPC to include new information on the variability of response to clopidogrel due to either genetic variations of the CYP2C19 enzyme or concomitant use of drugs that inhibit the CYP2C19 enzyme such as proton pump inhibitor (PPI). In addition, section 4.8 has been amended with minor details on the CURE study. |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                |            |     |             | Additional changes have been added to the SPC and Package Leaflet in order to bring it in line with the revised QRD template (version 7.3). Additionally Annex II was updated with regards to Pharmacovigilance system. We also made minor correction in List of local representatives for Estonia, Lativa, Poland, Austria, Greece, Lithuania, Cyprus and United Kingdom.   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0003 | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size                                                                                    | 20/12/2010 | n/a |             |                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0002 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH | 22/07/2010 | n/a | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0001 | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                                                                                                                     | 17/11/2009 | n/a | SmPC        |                                                                                                                                                                                                                                                                                                                                                                              |